Literature DB >> 7163813

Toxicity of single- vs. fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study.

L R Morgan, E F Harrison, J E Hawke, H L Hunter, J J Costanzi, D Plotkin, W G Tucker, P M Worrall.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7163813

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  19 in total

Review 1.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

2.  The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump.

Authors:  J A Radford; J M Margison; R Swindell; M J Lind; P M Wilkinson; N Thatcher
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

3.  The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump.

Authors:  J A Radford; J M Margison; R Swindell; M J Lind; P M Wilkinson; N Thatcher
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 4.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

5.  6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies.

Authors:  E C Brain; A Mita; P Soulié; H Errihani; A C Hardy Bessard; M Chaouche; J Alexandre; J P Delord; E Cvitkovic; C Jasmin; J L Misset
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

6.  Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity.

Authors:  D M Nanus; D P Kelsen; R Lipperman; M Eisenberger
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

7.  A phase II study of ifosfamide in children with recurrent solid tumours.

Authors:  C R Pinkerton; H Rogers; C James; A Bowman; P R Barbor; O B Eden; J Pritchard
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 8.  Dosing and side-effects of ifosfamide plus mesna.

Authors:  W P Brade; K Herdrich; U Kachel-Fischer; C E Araujo
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

9.  Metabolism and pharmacokinetics of oral and intravenous ifosfamide.

Authors:  V Kurowski; T Cerny; A Küpfer; T Wagner
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

10.  Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study.

Authors:  T M Loeffler; F W Weber; T U Hausamen
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.